Drug Watch

Latest News

Results of Phase 3 BE HEARD Trials of Bimekizumab for HS Published in The Lancet
Results of Phase 3 BE HEARD Trials of Bimekizumab for HS Published in The Lancet

May 23rd 2024

The Lancet data is the primary publication of bimekizumab results from BE HEARD I and BE HEARD II.

FDA Updates PDUFA Date of Subcutaneous Nivolumab
FDA Updates PDUFA Date of Subcutaneous Nivolumab

May 22nd 2024

Baldo Scassellati Sforzolini, MD, PhD, MBA: Expanding Nemolizumab’s Access
Baldo Scassellati Sforzolini, MD, PhD, MBA: Expanding Nemolizumab’s Access

May 17th 2024

MoonLake’s Sonelokimab Trial for HS Advances to Phase 3
MoonLake’s Sonelokimab Trial for HS Advances to Phase 3

May 16th 2024

Deucravacitinib Demonstrates Sustained Efficacy and Safety in 4-Year Psoriasis Trial
Deucravacitinib Demonstrates Sustained Efficacy and Safety in 4-Year Psoriasis Trial

May 16th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.